BRPI0712225A8 - métodos para prever e monitorar a eficácia da terapia antagonista de igf-1r - Google Patents
métodos para prever e monitorar a eficácia da terapia antagonista de igf-1rInfo
- Publication number
- BRPI0712225A8 BRPI0712225A8 BRPI0712225A BRPI0712225A BRPI0712225A8 BR PI0712225 A8 BRPI0712225 A8 BR PI0712225A8 BR PI0712225 A BRPI0712225 A BR PI0712225A BR PI0712225 A BRPI0712225 A BR PI0712225A BR PI0712225 A8 BRPI0712225 A8 BR PI0712225A8
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- igf
- antagonist therapy
- predict
- effectiveness
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5064—Endothelial cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4742—Keratin; Cytokeratin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4745—Insulin-like growth factor binding protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Sampling And Sample Adjustment (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
métodos para prever e monitorar a eficácia da terapia antagonista de igf-1r. são apresentados métodos para a detecção, contagem e análise de células circulantes de tumor que expressam receptores de fator 1 de crescimento semelhante à insulina (igf-1 r). estes métodos são úteis para a pesquisa de câncer e o estadiamento, desenvolvimento de regimes de tratamento, e para a monitoração de respostas ao tratamento, recorrência de câncer ou semelhante. são também apresentados conjuntos de teste que facilitam a detecção, contagem e análise de tais células circulantes de tumor.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81081106P | 2006-06-02 | 2006-06-02 | |
US60/810.811 | 2006-06-02 | ||
PCT/IB2007/001483 WO2007141626A1 (en) | 2006-06-02 | 2007-05-29 | Circulating tumor cell assay |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0712225A2 BRPI0712225A2 (pt) | 2012-07-24 |
BRPI0712225A8 true BRPI0712225A8 (pt) | 2019-01-22 |
Family
ID=38476880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0712225A BRPI0712225A8 (pt) | 2006-06-02 | 2007-05-29 | métodos para prever e monitorar a eficácia da terapia antagonista de igf-1r |
Country Status (20)
Country | Link |
---|---|
US (4) | US8940493B2 (pt) |
EP (1) | EP2027470B1 (pt) |
JP (1) | JP4943504B2 (pt) |
KR (3) | KR20090023423A (pt) |
CN (1) | CN101600966B (pt) |
AU (1) | AU2007255110B8 (pt) |
BR (1) | BRPI0712225A8 (pt) |
CA (1) | CA2653745C (pt) |
DK (1) | DK2027470T3 (pt) |
ES (1) | ES2397971T3 (pt) |
HK (1) | HK1137509A1 (pt) |
IL (1) | IL195577A (pt) |
MX (1) | MX2008015425A (pt) |
NZ (1) | NZ573187A (pt) |
PL (1) | PL2027470T3 (pt) |
PT (1) | PT2027470E (pt) |
RU (1) | RU2429486C2 (pt) |
SI (1) | SI2027470T1 (pt) |
WO (1) | WO2007141626A1 (pt) |
ZA (1) | ZA200810203B (pt) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006292278B2 (en) | 2005-09-20 | 2012-03-08 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
DK2027470T3 (da) | 2006-06-02 | 2013-02-04 | Pfizer Prod Inc | Analyse for cirkulerende tumorceller |
PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
WO2009045389A2 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
CA2694154A1 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20090258365A1 (en) | 2008-03-25 | 2009-10-15 | Terstappen Leon W M M | METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH |
CN103396488A (zh) | 2008-12-12 | 2013-11-20 | 贝林格尔.英格海姆国际有限公司 | 抗igf抗体 |
JP6352588B2 (ja) * | 2009-10-21 | 2018-07-04 | ザ スクリプス リサーチ インスティテュート | 希少ではない細胞を用いて希少細胞を検出する方法 |
WO2011083391A2 (en) * | 2010-01-05 | 2011-07-14 | Pfizer Inc. | Biomarkers for anti-igf-ir cancer therapy |
ES2634220T3 (es) * | 2010-10-14 | 2017-09-27 | Janssen Diagnostics, Llc | Métodos y kits para la detección de células tumorales circulantes en pacientes pancreáticos utilizando reactivos poliespecíficos de captura y coctel de detección |
US20140308669A1 (en) * | 2011-01-24 | 2014-10-16 | Epic Science, Inc. | Methods for obtaining single cells and applications of single cell omics |
US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
DK2734307T3 (da) | 2011-07-21 | 2020-06-02 | Menarini Silicon Biosystems Spa | Assay til at indsamle og detektere cirkulerende multiple myelomceller fra blod |
ES2930651T3 (es) * | 2011-09-06 | 2022-12-20 | Becton Dickinson Co | Métodos y composiciones para la detección citométrica de células tumorales circulantes en una muestra |
GB2539836B (en) | 2012-08-13 | 2017-03-29 | Univ California | Methods for detecting target nucleic acids in sample lysate droplets |
AR092908A1 (es) * | 2012-10-05 | 2015-05-06 | Genentech Inc | Metodos para diagnosticar y tratar enfermedad intestinal inflamatoria |
EP2912433B1 (en) * | 2012-10-26 | 2019-03-20 | Fluidigm Canada Inc. | Cell analysis by mass cytometry |
US9396532B2 (en) * | 2012-11-15 | 2016-07-19 | Siemens Healthcare Diagnostics, Inc. | Cell feature-based automatic circulating tumor cell detection |
JP6509745B2 (ja) | 2013-01-25 | 2019-05-08 | エックスセル・バイオサイエンシズ・インコーポレイテッド | 標的細胞の選択的富化のための方法、組成物、キット、及びシステム |
US20150233932A1 (en) * | 2013-02-19 | 2015-08-20 | Ching-Ping Tseng | Methods, Systems, and Compositions for Enrichment of Rare Cells |
US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
EP3683321B1 (en) * | 2013-10-21 | 2021-12-08 | The General Hospital Corporation | Methods relating to circulating tumor cell clusters and the treatment of cancer |
CN103630440A (zh) * | 2013-11-28 | 2014-03-12 | 武汉大学 | 一种循环肿瘤细胞的富集方法 |
EP3100047B1 (en) | 2014-01-27 | 2021-08-11 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for prostate cancer biomarkers |
CN106061998B (zh) * | 2014-02-05 | 2020-12-11 | 弗吉瑞必欧诊断股份公司 | 用于检测恶性赘生性疾病的组合物和方法 |
WO2015127008A1 (en) | 2014-02-21 | 2015-08-27 | Epic Sciences, Inc. | Methods for analyzing rare circulating cells |
CN103940997B (zh) * | 2014-03-21 | 2017-01-04 | 上海柏慧康生物科技有限公司 | 一种乳腺癌循环肿瘤细胞检测***及试剂盒 |
KR101656037B1 (ko) * | 2014-04-30 | 2016-09-08 | 울산과학기술원 | 희소 세포 분리장치, 희소 세포 분리 방법 및 이를 이용한 희소 세포 검출 방법 |
WO2015200717A2 (en) | 2014-06-27 | 2015-12-30 | The Regents Of The University Of California | Pcr-activated sorting (pas) |
CN104345052B (zh) * | 2014-09-29 | 2017-10-20 | 南通市肿瘤医院 | 一种荧光负染法检测活细胞的方法 |
WO2016065056A1 (en) | 2014-10-22 | 2016-04-28 | The Regents Of The University Of California | High definition microdroplet printer |
CA2974306A1 (en) | 2015-02-04 | 2016-08-11 | The Regents Of The University Of California | Sequencing of nucleic acids via barcoding in discrete entities |
CA2981543A1 (en) * | 2015-04-22 | 2016-10-27 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
KR101701618B1 (ko) | 2015-06-23 | 2017-02-13 | 국립암센터 | 전도성 고분자를 이용한 세포 유리 dna 검출용 구조체 및 이의 용도 |
RU2616532C1 (ru) * | 2015-12-28 | 2017-04-17 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ оценки чувствительности опухоли к проводимой химиотерапии больных местно-распространенным раком молочной железы |
KR102130872B1 (ko) | 2016-04-27 | 2020-07-06 | 주식회사 엘지화학 | 고체 시료의 수분 측정 장치, 고체 시료 수분 함량 측정 방법 및 이미드화율 분석 방법 |
CN110088290A (zh) | 2016-08-10 | 2019-08-02 | 加利福尼亚大学董事会 | 在乳液微滴中结合多重置换扩增和pcr |
AU2017382905A1 (en) | 2016-12-21 | 2019-07-04 | The Regents Of The University Of California | Single cell genomic sequencing using hydrogel based droplets |
CN115969102A (zh) | 2017-04-05 | 2023-04-18 | 菲利普莫里斯生产公司 | 与电感加热式气溶胶生成装置或***一起使用的感受器 |
US11576424B2 (en) | 2017-04-05 | 2023-02-14 | Altria Client Services Llc | Susceptor for use with an inductively heated aerosol-generating device or system |
US10501739B2 (en) | 2017-10-18 | 2019-12-10 | Mission Bio, Inc. | Method, systems and apparatus for single cell analysis |
EP3540631A1 (de) * | 2018-03-15 | 2019-09-18 | Siemens Healthcare GmbH | In-vitro-verfahren zum markierungsfreien bestimmen eines zelltyps einer weissen blutzelle |
CN109406245A (zh) * | 2018-09-12 | 2019-03-01 | 中国辐射防护研究院 | 一种电子线照射对小鼠igf相关蛋白表达影响的检测方法 |
AU2020280104A1 (en) | 2019-05-22 | 2022-01-20 | Mission Bio, Inc. | Method and apparatus for simultaneous targeted sequencing of DNA, RNA and protein |
US11667954B2 (en) | 2019-07-01 | 2023-06-06 | Mission Bio, Inc. | Method and apparatus to normalize quantitative readouts in single-cell experiments |
WO2024148280A1 (en) | 2023-01-06 | 2024-07-11 | Ideaya Biosciences, Inc. | Treatment of er+ breast cancer comprising homologous recombination deficiency using parc inhibitor |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4551435A (en) * | 1983-08-24 | 1985-11-05 | Immunicon, Inc. | Selective removal of immunospecifically recognizable substances from solution |
US4795698A (en) * | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
US4925788A (en) * | 1986-10-24 | 1990-05-15 | Immunicon Corporation | Immunoassay system and procedure based on precipitin-like interaction between immune complex and Clq or other non-immunospecific factor |
US5108933A (en) * | 1988-09-16 | 1992-04-28 | Immunicon Corporation | Manipulation of colloids for facilitating magnetic separations |
US5200084A (en) * | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
WO1997038313A1 (en) * | 1996-04-05 | 1997-10-16 | The Johns Hopkins University | A method of enriching rare cells |
US20010018192A1 (en) | 1998-02-12 | 2001-08-30 | Terstappen Leon W.M.M. | Labeled cells for use as an internal functional control in rare cell detection assays |
US20020172987A1 (en) * | 1998-02-12 | 2002-11-21 | Terstappen Leon W.M.M. | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
IL137802A0 (en) | 1998-02-12 | 2001-10-31 | Immunivest Corp | A method and kit for detecting rare cells in a mixed cell population |
GB2361996B (en) | 1998-10-29 | 2004-05-12 | Cell Works Inc | Multiple marker characterization of single cells |
US6960449B2 (en) * | 1999-02-10 | 2005-11-01 | Cell Works Diagnostics, Inc. | Class characterization of circulating cancer cells isolated from body fluids and methods of use |
JP2001041959A (ja) | 1999-05-24 | 2001-02-16 | Toray Ind Inc | 癌細胞検出システムおよび癌細胞検出キット |
CN1753686A (zh) | 1999-08-18 | 2006-03-29 | 综合医院公司 | 用于促进从中枢神经***损伤中恢复的方法、组合物和试剂盒 |
US7537938B2 (en) * | 2000-04-28 | 2009-05-26 | Monogram Biosciences, Inc. | Biomarker detection in circulating cells |
NZ526924A (en) * | 2001-01-23 | 2005-09-30 | Primagen Holding B | Means and methods for treatment evaluation |
JP2005516217A (ja) | 2001-02-16 | 2005-06-02 | イムニベスト・コーポレイション | 循環している癌細胞の急速かつ効果的な単離のための方法および試薬 |
US7863012B2 (en) * | 2004-02-17 | 2011-01-04 | Veridex, Llc | Analysis of circulating tumor cells, fragments, and debris |
BR0212124A (pt) * | 2001-08-23 | 2004-07-20 | Immunivest Corp | Composições, métodos e aparelhos para conservar espécimes biológicos e amostras de sangue suspeitas de conter células tumorais circulantes, e, composição celular estabilizada |
US6670142B2 (en) * | 2001-10-26 | 2003-12-30 | The Regents Of The University Of California | Method for screening combinatorial bead library, capturing cells from body fluids, and ligands for cancer cells |
ES2283759T3 (es) * | 2002-01-18 | 2007-11-01 | Pierre Fabre Medicament | Anticuerpos anti-igf-ir y sus aplicaciones. |
US20040229294A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
ES2351395T3 (es) * | 2003-08-13 | 2011-02-04 | Pfizer Products Inc. | Anticuerpos humanos modificados anti-igf-1r. |
EP1802341A1 (en) * | 2004-07-16 | 2007-07-04 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
US20060045881A1 (en) * | 2004-08-26 | 2006-03-02 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
WO2006041453A1 (en) | 2004-09-30 | 2006-04-20 | Immunivest Corporation | Circulating tumor cells (ctc’s): apoptotic assessment in prostate cancer patients |
DK1861509T3 (da) | 2005-03-14 | 2015-12-07 | Janssen Diagnostics Llc | Fremgangsmåde til forudsigelse af progressionsfri og overordnet overlevelse for hvert opfølgningstidspunkt under behandling af patienter med metastatisk brystkræft under anvendelse af cirkulerende tumorceller |
US20070037173A1 (en) * | 2005-08-12 | 2007-02-15 | Allard Jeffrey W | Circulating tumor cells (CTC's): early assessment of time to progression, survival and response to therapy in metastatic cancer patients |
DK2027470T3 (da) | 2006-06-02 | 2013-02-04 | Pfizer Prod Inc | Analyse for cirkulerende tumorceller |
CA2971968C (en) * | 2007-10-24 | 2019-08-13 | Biomarker Strategies, Llc | Improved methods and devices for cellular analysis |
-
2007
- 2007-05-29 DK DK07734765.6T patent/DK2027470T3/da active
- 2007-05-29 BR BRPI0712225A patent/BRPI0712225A8/pt not_active Application Discontinuation
- 2007-05-29 SI SI200731093T patent/SI2027470T1/sl unknown
- 2007-05-29 US US12/303,243 patent/US8940493B2/en active Active
- 2007-05-29 RU RU2008147415/15A patent/RU2429486C2/ru not_active IP Right Cessation
- 2007-05-29 KR KR1020087032034A patent/KR20090023423A/ko active Application Filing
- 2007-05-29 PL PL07734765T patent/PL2027470T3/pl unknown
- 2007-05-29 CN CN200780027121.3A patent/CN101600966B/zh not_active Expired - Fee Related
- 2007-05-29 EP EP07734765A patent/EP2027470B1/en not_active Not-in-force
- 2007-05-29 KR KR1020147009331A patent/KR20140052081A/ko not_active Application Discontinuation
- 2007-05-29 CA CA2653745A patent/CA2653745C/en not_active Expired - Fee Related
- 2007-05-29 ES ES07734765T patent/ES2397971T3/es active Active
- 2007-05-29 MX MX2008015425A patent/MX2008015425A/es active IP Right Grant
- 2007-05-29 KR KR1020137019896A patent/KR101467136B1/ko active IP Right Grant
- 2007-05-29 WO PCT/IB2007/001483 patent/WO2007141626A1/en active Application Filing
- 2007-05-29 AU AU2007255110A patent/AU2007255110B8/en not_active Ceased
- 2007-05-29 PT PT77347656T patent/PT2027470E/pt unknown
- 2007-05-29 NZ NZ573187A patent/NZ573187A/en not_active IP Right Cessation
- 2007-05-29 JP JP2009512704A patent/JP4943504B2/ja not_active Expired - Fee Related
-
2008
- 2008-11-27 IL IL195577A patent/IL195577A/en active IP Right Grant
- 2008-12-01 ZA ZA2008/10203A patent/ZA200810203B/en unknown
-
2010
- 2010-01-29 HK HK10100979.3A patent/HK1137509A1/xx not_active IP Right Cessation
-
2014
- 2014-12-22 US US14/580,019 patent/US20150177252A1/en not_active Abandoned
-
2017
- 2017-07-27 US US15/661,241 patent/US20180011103A1/en not_active Abandoned
-
2019
- 2019-07-08 US US16/505,085 patent/US20200191793A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0712225A8 (pt) | métodos para prever e monitorar a eficácia da terapia antagonista de igf-1r | |
WO2019156568A8 (en) | Methods for predicting treatment outcome and/or for selecting a subject suitable for immune checkpoint therapy | |
BR112015023120A2 (pt) | método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado | |
BRPI0915619A2 (pt) | métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra | |
BRPI0915240A2 (pt) | método para tratar câncer, método para avaliação de um paciente submetido ao tratamento de câncer, método para avaliação de um paciente que tem ou com suspeita de ter câncer e uso de um anticorpo anti-c-met | |
EP3839510A3 (en) | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists | |
WO2009067546A3 (en) | Lung cancer markers and uses thereof | |
EP4293358A3 (en) | Volatile organic compounds as cancer biomarkers | |
BR112013006528A2 (pt) | fosfolipidoma de câncer | |
EP2637020A3 (en) | Predictive markers for ovarian cancer | |
EA201590630A1 (ru) | Способы лечения и диагностики, связанные с лизилоксидазоподобным белком 2 (loxl2) | |
BR0207290A (pt) | Método para analisar um paciente quanto à presença de uma malignidade, célula maligna isolada das células cultivadas, vacina de tumor, molécula associada com diátese de tumor alterada, métodos para determinar alterações em moléculas associadas com diátese de tumor como um meio para predizer a eficácia da terapia, como um meio para analisar dosagem apropriada para terapia, como um meio para monitorar eficácia da terapia, como um meio para analisar progressão de câncer, para realizar uma biópsia de corpo inteiro em um paciente, e para identificar alterações em uma célula de tumor circulante relativamente a células presentes numa massa de tumor in situ, e, kit de teste para analisar uma amostra de paciente quanto à presença de uma célula maligna não-hematopoiética | |
WO2005085860A3 (en) | New proliferation markers in clinical practice and their use for cancer prognosis or diagnosis | |
TW200626899A (en) | Frizzled proteins and detection and treatment of cancer | |
WO2008036835A3 (en) | Methods and compositions for upregulation of peroxiredoxin activity | |
WO2008089135A3 (en) | Identification of biomarkers predictive of dasatinib effects in cancer cells | |
WO2012050365A3 (ko) | 교모세포종의 진단 또는 예후 예측용 바이오 마커 및 그 용도 | |
EA201491411A1 (ru) | Растворимый manf при поражениях бета-клеток поджелудочной железы | |
AR071034A1 (es) | Uso de la catepsina c en el diagnostico de susceptibilidad al dolor y para el tratamiento del dolor | |
DE602005013430D1 (de) | Verwendung von asc als marker für kolorektalkarzinome | |
Brown et al. | Using patient-derived xenograft models of colorectal liver metastases to predict chemosensitivity | |
DK1791973T3 (da) | DOT1-histonmethyltransferaser som et target til at identificere terapeutiske midler mod leukæmi | |
ZA200807766B (en) | Inhibition of GASC1 | |
Thomas et al. | Targeted proteomic analyses of histone H4 acetylation changes associated with homologous-recombination-deficient high-grade serous ovarian carcinomas | |
WO2008060833A3 (en) | Composition, method, system, and kit for optical electrophysiology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: ESCLARECA A DIVERGENCIA NO SOBRENOME DO SETIMO INVENTOR CONSTANTE NA PUBLICACAO INTERNACIONAL WO2007/141626 A1, "TERSTAPPEN", E O CONSTANTE NA PETICAO DE ENTRADA NA FASE NACIONAL, "STAPPEN". |
|
B25A | Requested transfer of rights approved |
Owner name: PFIZER PRODUCS INC. (US) , VERIDEX, LLC (US) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |